Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an update.
Cosmo Pharmaceuticals has made significant strides in its ESG initiatives, achieving an upgrade in its MSCI ESG rating to ‘A’ and doubling its LSEG ESG score, reflecting its commitment to sustainability. By joining the UN Global Compact and committing to the Science Based Targets Initiative, Cosmo positions itself as a leader in sustainable healthcare, aligning its operations with global standards and attracting ESG-focused investments.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company develops advanced medical solutions and collaborates with leading global pharma and MedTech companies to enhance patient care. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in the USA and Italy.
Average Trading Volume: 24,263
Current Market Cap: CHF1.05B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.